Table 2.
Acute (n = 57) |
Late (n = 57) |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Grade |
Grade |
|||||||||
0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | |
Skin | 2 | 49 | 4 | 2 | 0 | 9 | 47 | 1 | 0 | 0 |
Liver∗ | 36 | 16 | 5 | 0 | 0 | 24 | 28 | 3 | 0 | 0 |
Gastrointestinal | 57 | 0 | 0 | 0 | 0 | 57 | 0 | 0 | 0 | 0 |
Lung | 45 | 12 | 0 | 0 | 0 | 33 | 24 | 0 | 0 | 0 |
Bone | 57 | 0 | 0 | 0 | 0 | 56 | 0 | 1 | 0 | 0 |
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
Two patients who developed multiple recurrence in the liver and underwent TACE at 3 months after CIRT were excluded from evaluation for late hepatic toxicities.